TandemAI, a drug discovery technology company, has raised $22 million in a Series A extension round led by V-Capital and KHK Fund. The investment will enable the company to further develop its AI and computational physics-based models while expanding laboratory operations to meet increasing client demand.
TandemAI’s proprietary platform, TandemViz, integrates experimental and computational data to streamline drug discovery processes. The web-based platform supports data visualization and facilitates the connection of disparate research information, allowing users to directly access external repositories and enhance research efficiency.
“The financing is a strong vote of confidence in our progress to date and in our strategy,” said Jeff He, cofounder and CEO of TandemAI. “This funding will support AI and computational physics-based model development for multiple modalities, as well as wet lab capacity expansion to accommodate our rapidly growing client base.”
The new funding follows TandemAI’s 2023 Series A round of $35 million led by Qiming Venture Partners with participation from Eight Roads Ventures, OrbiMed, and F-Prime Capital. That investment was directed toward scaling integrated computational tools and biophysical wet lab capabilities.
In July 2025, TandemAI merged with Perpetual Medicines, combining resources under the TandemAI brand to provide an expanded suite of methods for small-molecule and peptide drug discovery. The merger broadened the company’s research offerings and reinforced its position within the competitive AI-driven pharmaceutical sector.
The current financing positions TandemAI among a growing list of AI-enabled drug discovery companies attracting investor interest. Iambic, for example, recently closed an oversubscribed $100 million round, while Manas AI launched in January with $24.6 million in seed funding to scale its AI-driven drug discovery and development platform.
Through this latest capital infusion, TandemAI aims to accelerate model development, broaden its technological capabilities, and strengthen its role in advancing multi-modality drug discovery through AI and computational innovation.
Click here for the original news story.